Transaction DateRecipientSharesTypePriceValue
17th September 2020Ron Cohen8,543Grant/award etc.$0.00
17th September 2020Burkhard Blank3,015Grant/award etc.$0.00
17th September 2020David Lawrence3,015Grant/award etc.$0.00
17th September 2020Lauren M Sabella3,015Grant/award etc.$0.00
20th August 2020Andrew A. Hindman4,323Payment by withholding$18.22$78,765.06
27th July 2020Andrew A. Hindman20,000Grant/award etc.$0.00
20th February 2020Andrew A. Hindman7,060Payment by withholding$25.90$182,854.00
3rd February 2020Andrew A. Hindman20,000Grant/award etc.$0.00
3rd February 2020Andrew A. Hindman43,550Grant/award etc.$0.00
2nd December 2019Jane Wasman2,227Open or private sale$1.60$3,552.73
Acorda Therapeutics
Acorda Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.


Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.


Ticker: ACOR
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1008848
Employees: 344
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $41 M (0%)
Inventory, Net: $33 M (0%)
Other Assets, Current: $3 M (-18%)
Assets, Current: $158 M (-21%)
Property, Plant and Equipment, Net: $142 M (0%)
Other Assets, Noncurrent: $11 Th (-62%)
Assets: $728 M (-8%)
Accounts Payable, Current: $15 M (-44%)
Accrued Liabilities, Current: $37 M (-4%)
Liabilities, Current: $138 M (60%)
Other Liabilities, Noncurrent: $989 Th (281%)
Common Stock, Value, Issued: $48 Th (0%)
Common Stock, Shares, Issued: $48 M (0%)
Additional Paid in Capital, Common Stock: $983 M (0%)
Retained Earnings (Accumulated Deficit): $691 M (3%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $1 M (4%)
Treasury Stock, Value: $6 Th (0%)
Treasury Stock, Shares: $293 Th (0%)
Stockholders' Equity (Parent): $291 M (-6%)
Liabilities and Equity: $728 M (-8%)
Revenue: $34 M (0%)
Cost of Revenue: $7 M (-36%)
Research and Development: $5 M (-59%)
Operating Income/Loss: $10 M (-39%)
Other Income, net: $7 M (-50%)
Provision for income taxes: $571 Th (-4%)
EPS (basic): $0.37 (0%)
EPS (diluted): $0.37 (0%)